MARKET

CDNA

CDNA

CareDx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.94
-1.37
-4.11%
Opening 14:59 09/23 EDT
OPEN
33.35
PREV CLOSE
33.31
HIGH
33.73
LOW
31.71
VOLUME
241.32K
TURNOVER
--
52 WEEK HIGH
37.55
52 WEEK LOW
13.04
MARKET CAP
1.56B
P/E (TTM)
-72.9390
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CareDx Shares Latest Clinical Data at the TTS 2020 Virtual Conference
AlloSure and AlloSeq cfDNA surveillance tools to be featured along with four virtual symposia at international congressSOUTH SAN FRANCISCO, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization
GlobeNewswire · 09/11 12:00
CareDx To Present Clinical Data At TTS 2020 Virtual Conference Sept. 13-15
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc.(NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated,
Benzinga · 09/11 11:01
CareDx Strengthens Leadership Team to Accelerate Growth
CareDx appoints key hires in digital services, laboratory operations, business development and market accessSOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of
GlobeNewswire · 09/10 12:00
CareDx to Participate at Upcoming Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced
GlobeNewswire · 09/02 12:00
KEYS, KDMN, CDNA and MOBL among after-hours movers
Gainers: [[MOBL]] +9.6%. [[REDU]] +5.2%. [[KEYS]] +5.1%. [[GLDD]] +4.5%. [[XERS]] +4.4%.Losers: [[BBQ]] -10.6%. [[HKIB]] -8.6%. [[KDMN]] -6.1%. [[CATO]] -3.9%. [[CDNA]] -3.3%.
Seekingalpha · 08/20 21:42
Raymond James Maintains Strong Buy on CareDx, Raises Price Target to $42
Raymond James maintains CareDx (NASDAQ:CDNA) with a Strong Buy and raises the price target from $40 to $42.
Benzinga · 08/05 11:17
Raymond James Maintains Strong Buy on CareDx, Raises Price Target to $42
Raymond James maintains CareDx (NASDAQ:CDNA) with a Strong Buy and raises the price target from $40 to $42.
Benzinga · 08/05 11:17
CareDx EPS beats by $0.08, beats on revenue
CareDx (NASDAQ:CDNA): Q2 Non-GAAP EPS of $0.04 beats by $0.08; GAAP EPS of -$0.15 in-line. Revenue of $41.8M (+32.9% Y/Y) beats by $6.19M. Press Release
seekingalpha · 08/05 01:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDNA. Analyze the recent business situations of CareDx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDNA stock price target is 44.50 with a high estimate of 54.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 279
Institutional Holdings: 61.13M
% Owned: 124.85%
Shares Outstanding: 48.96M
TypeInstitutionsShares
Increased
54
5.48M
New
71
2.73M
Decreased
60
8.55M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.79%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
Peter Maag
President
Reginald Seeto
Chief Financial Officer
Michael Bell
Chief Marketing Officer
Sasha King
Lead Director/Independent Director
Michael Goldberg
Independent Director
George Bickerstaff
Independent Director
Frederick Cohen
Independent Director
Grace Colon
Independent Director
Christine Cournoyer
Independent Director
William Hagstrom
Independent Director
Fred Cohen
Independent Director
Ralph Snyderman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CDNA
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CareDx Inc stock information, including NASDAQ:CDNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDNA stock methods without spending real money on the virtual paper trading platform.